These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 34741547)
21. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460 [TBL] [Abstract][Full Text] [Related]
22. Performance of whole-body Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):847-855. PubMed ID: 30604061 [TBL] [Abstract][Full Text] [Related]
23. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients. Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023 [TBL] [Abstract][Full Text] [Related]
25. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Kumar R; Alavi A Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921 [TBL] [Abstract][Full Text] [Related]
26. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients. Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET. Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889 [TBL] [Abstract][Full Text] [Related]
29. Clinical value of whole body Bower N; Morris A; O'Connor J; Sponagle M; Bahr R; Gilbert R; Mohamed A; Bower J J Med Imaging Radiat Sci; 2024 Jun; 55(2):212-220. PubMed ID: 38403520 [TBL] [Abstract][Full Text] [Related]
30. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma. Lee JW; Nam SB; Kim SJ Oncology; 2019; 97(5):286-293. PubMed ID: 31437839 [TBL] [Abstract][Full Text] [Related]
31. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence. Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338 [TBL] [Abstract][Full Text] [Related]
32. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland. Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255 [TBL] [Abstract][Full Text] [Related]
33. Role of Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903 [TBL] [Abstract][Full Text] [Related]
34. Use of Diffusion-Weighted Imaging and Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343 [TBL] [Abstract][Full Text] [Related]
35. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Te Marvelde L; Herschtal A; Spillane J; Gyorki D; Speakman D; Estall V; Donahoe S; Pohl M; Pope K; Chua M; Sandhu S; McArthur GA; McCormack CJ; Henderson M; Hicks RJ; Shackleton M Ann Oncol; 2018 Jul; 29(7):1569-1574. PubMed ID: 29659679 [TBL] [Abstract][Full Text] [Related]
36. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249 [TBL] [Abstract][Full Text] [Related]
37. FDG PET in early stage cutaneous malignant melanoma. McIvor J; Siew T; Campbell A; McCarthy M J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243 [TBL] [Abstract][Full Text] [Related]
38. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370 [TBL] [Abstract][Full Text] [Related]
39. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma. Bikhchandani J; Wood J; Richards AT; Smith RB Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077 [TBL] [Abstract][Full Text] [Related]
40. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results. Sun L; Su XH; Guan YS; Pan WM; Luo ZM; Wei JH; Wu H World J Gastroenterol; 2008 Aug; 14(29):4627-32. PubMed ID: 18698676 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]